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High aldehyde dehydrogenase (ALDH) activity has been associated with stem and progenitor cells in various tissues. Human cord
blood and bonemarrowALDH-bright (ALDHbr) cells have displayed angiogenic activity in preclinical studies and have been shown
to be safe in clinical trials in patients with ischemic cardiovascular disease. e presence of ALDHbr cells in the heart has not been
evaluated so far. We have characterized ALDHbr cells isolated frommouse hearts. One percent of nonmyocytic cells from neonatal
and adult hearts wereALDHbr. ALDHvery-br cells weremore frequent in neonatal hearts than adult. ALDHbr cells weremore frequent
in atria than ventricles. Expression of ALDH1A1 isozyme transcripts was highest in ALDHvery-br cells, intermediate in ALDHbr
cells, and lowest in ALDHdim cells. ALDH1A2 expression was highest in ALDHvery-br cells, intermediate in ALDHdim cells, and
lowest in ALDHbr cells. ALDH1A3 and ALDH2 expression was detectable in ALDHvery-br and ALDHbr cells, unlike ALDHdim cells,
albeit at lower levels compared with ALDH1A1 and ALDH1A2. Freshly isolated ALDHbr cells were enriched for cells expressing
stem cell antigen-1, CD34, CD90, CD44, and CD106. ALDHbr cells, unlike ALDHdim cells, could be grown in culture for more
than 40 passages.ey expressed sarcomeric 𝛼𝛼-actinin and could be diﬀerentiated along multiple mesenchymal lineages. However,
the proportion of ALDHbr cells declined with cell passage. In conclusion, the cardiac-derived ALDHbr population is enriched for
progenitor cells that exhibitmesenchymal progenitor-like characteristics and can be expanded in culture.e regenerative potential
of cardiac-derived ALDHbr cells remains to be evaluated.
1. Introduction
Growing evidence suggests the adult heart may harbor
resident stem and progenitor cells that participate in adaptive
responses to myocardial injury, and possibly in cellular
homeostasis under normal conditions. In most studies, the
prospective isolation of cardiac stem cells has relied upon
the use of speci�c antibodies that recognize cell-surface
antigens expressed by stem cells in other tissues, particularly
by hematopoietic stem cells (HSCs). Cardiac stem cells
expressing stem cell antigen-1 (Sca-1) or the stem cell factor
receptor, c-kit (CD117), have been described [1, 2]. A distinct
population of cardioblasts expressing the transcription factor
islet-1 (Isl-1) and entering fully diﬀerentiated cardiomy-
ocyte lineages has also been identi�ed [3, 4]. However,
the expression of cell-surface epitopes can vary with the
metabolic state of the cell and the experimental conditions
used. erefore, no individual cell-surface antigen marker
de�nitely identi�es a single entity of cardiac stem cell.
Functional properties of tissue-resident stem cells that could
be used for their prospective isolation, regardless of cell-
surface marker expression, have been intensely searched for.
It has been proposed that, irrespective of their lineal origin,
stem cells may share common mechanisms to regulate self-
renewal and diﬀerentiation, and that candidate “stemness”
genes may serve as universal stem cell markers.
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Cai et al. [5] proposed that high aldehyde dehydrogenase
(ALDH) activity is one of a small set of common character-
istics shared by stem cells among tissues (recently reviewed
by Balber [6]). Few ALDH-bright (ALDHbr) pluripotential
cells, measured by Alde�uor stain, gave rise to all somatic
and reproductive cell lineages in tunicates [7, 8]. ALDH is
a cytosolic enzyme responsible for the oxidation of intra-
cellular aldehydes. It plays important roles in oxidation of
alcohol and vitamin A, and in chemoresistance to cyclophos-
phamide. ALDH superfamily is highly conserved across
species [9]. Nineteen ALDH isoforms are known in human.
ALDHbr, side scatter-low (SSClo) populations from murine
andhumanbonemarrow (BM) [10–13], umbilical cord blood
(UCB) [14–19], cytokine-mobilized peripheral blood [20],
and circulating blood cells [21, 22] are enriched in stem
and progenitor cells. e ALDHbrSSClo population includes
virtually all human CD34+ and CD133+ cells that establish
long-term, multilineage hematopoietic colonies in culture
or long-term, multilineage xenogras in immunode�cient
mice [16]. More recently, ALDHbr stem cells have been
identi�ed in nonhematopoietic systems, such as circulating
endothelial progenitor cells (EPCs) [21, 22], neural stem cells
[23, 24], human muscle precursor cells with high myogenic
activity [25, 26], colonic stem cells [27], and mammary stem
cells [28]. Moreover, ALDHbr cancer stem cells have been
described in multiple types of cancer and shown to predict
poor clinical outcomes in various contexts [27–29].
We therefore asked whether the postnatal heart harbors
ALDHbr cells, as measured by Alde�uor stain. We found
that the neonatal as well as the adult mouse heart harbors a
relatively small population of ALDHbr cells (≈1% of all non-
myocytic cells present in the heart), which is enriched for cells
expressing Sca-1 and other progenitor cell markers. ALDHbr
cells, but not ALDHdim cells, adhered to plastic and grew in
culture. e expanded population expressed sarcomeric 𝛼𝛼-
actinin, a cardiac marker, along with mesenchymal stem cell
(MSC) markers. It could be induced to diﬀerentiate along
multiplemesenchymal cell lineages.ese results suggest that
ALDH may mark a population of cardiac-resident, MSC-
like progenitor cells that possess superior ex vivo growth
characteristics.
2. Methods
2.1. Mice and Cell Isolation. Neonatal (postnatal day 1),
young adult (8 week-old), and aging (24 month-old) C57Bl/6
mice were purchased from Charles River Laboratories
(France). Immediately aer the sacri�ce of the mice, the
chest was opened, a canula was introduced into the le
ventricular cavity, an incision was made in the right atrial
wall, and the heart was perfused with heparinized PBS. e
explanted heart was washed in PBS and cut into small pieces
that were then placed in a Falcon tube (50mL) contain-
ing 5mL RPMI 1640 medium (Invitrogen, Carlsbad, CA,
USA) supplemented with 12.5𝜇𝜇L Liberase Blendzyme 4 and
25 𝜇𝜇L DNAse I (both from Roche, Basle, Switzerland), and
incubated for 45min at 37∘C under gentle shaking. e cell
suspension was �ltered through a 70𝜇𝜇m-�lter using a syringe
plunger, washed in PBS, and centrifuged. e pellet was
resuspended in 100 𝜇𝜇L Dead Cell Removal Kit microbeads
solution (Miltenyi, Bergisch Gladbach, Germany), incubated
for 15min at RT, changed to Dead Cell Removal Buﬀer, and
passaged through a Miltenyi LS column. e �ow-through
was centrifuged and the pellet was resuspended in FACS
buﬀer. In a subset of experiments, atria and ventricles were
processed separately tomeasure ALDHbr cells in the diﬀerent
cardiac chambers of origin.
2.2. Flow Cytometric Analyses. Cells were washed in PBS,
resuspended in Alde�uor buﬀer, and then reacted with
Alde�uor substrate (STEMCELL Technologies, �ancouver,
BC, Canada) according to the manufacturer’s instructions.
Aer the ALDH enzyme reaction, cells were washed, resus-
pended in cold Alde�uor buﬀer, and maintained on ice
during all subsequent manipulations. A forward scatter
(FSC) versus side scatter (SSC) cytogram was used to gate
signals from cells, and an Alde�uor �uorescence versus SSC
cytogram was constructed. A unique ALDHbr population
was present in Alde�uor-reacted samples and absent in cells
in the samples treated with the speci�c inhibitor of ALDH,
diethylaminobenzaldehyde (DEAB). Cells incubated with
Alde�uor substrate andDEABwere used to establish baseline
�uorescence of these cells and to de�ne the ALDHbr and
the ALDHvery-br region as less than 0.1% and 0% of total
events, respectively. Cell incubation with Alde�uor substrate
in the absence of inhibitor induced a shi in FL1 �uorescence
de�ning the ALDHdim, the ALDHbr, and the ALDHvery-br
population. To assess cell-surface antigen expression, cells
were incubated with antibody for 20min, washed, and resus-
pended in cold Alde�uor buﬀer. Flow cytometric analyses
were performed on a FACSCalibur instrument (BectonDick-
inson, San Jose, CA, USA) operating at 488 nm excitation
with standard emission �lters. Alde�uor �uorescence was
measured in FL1 and APC in FL4. Gates used to resolve
antigen-expressing cells were set using appropriate isotype-
matched control Abs. Data �les containing at least 2,000
ALDHbr cells were acquired for analysis using the CellQuest
soware (Becton Dickinson).
2.3. Immunostaining. Culture-expanded ALDHbr cells
grown in Lab-Tek chambers were �xed with 1%
paraformaldehyde (PFA) for 10min, followed by blocking
solution (1x PBS, 1% BSA, 0,3% Triton) for 1 h, and
incubated with rat anti-mouse c-Kit/CD117 mAb (clone
3C1; Miltenyi) coupled to APC for 1 h at RT, followed by
goat anti-rat IgG coupled to Alexa 488 (1 : 400 dilution;
Molecular Probes, Life Technologies, Grand Island, NY,
USA). To detect type II collagen, cells were �xed in PFA,
incubated in blocking solution for 1 h, and then with mouse
monoclonal anti-type II collagen 4 Abs coktail (1 : 100
dilution; Chondrex, Redmond, WA, USA), followed by
goat anti-mouse IgG coupled to Alexa 488 (1 : 400). To
detect sarcomeric 𝛼𝛼-actinin, cells were �xed with 4% PFA
for 1 h, incubated in blocking solution for 1 h, and then
with mouse antisarcomeric 𝛼𝛼-actinin mAb (1 : 750 dilution;
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clone EA-53, Sigma-Aldrich, St. Louis, MO, USA) at 4∘C
overnight, followed by goat anti-mouse IgG coupled to Alexa
488 (1 : 400). To detect 𝛼𝛼-smooth muscle actin (𝛼𝛼-SMA),
cells were stained with anti-𝛼𝛼-SMA rabbit polyclonal Ab
(abcam5694; Abcam). Control sections were incubated with
secondary Ab only. Nuclei were stained with Hoechst 33342
and slides were mounted with Mowiol. Pictures were taken
with a Zeiss Axioplant 2 microscope (100x objective).
2.4. Antibodies. e following mAbs were used to detect
the cell-surface antigen distribution of cardiac cells by �ow
cytometry: CD11b-APC (clone M1; Miltenyi), CD14-APC
(clone Sa2-8; eBioscience; San Diego, CA, USA), CD29-
PE (clone RTK2758; BioLegend), CD31-APC (clone 390;
eBioscience), CD34-APC (clone RAM-34; eBioscience),
CD38-APC (clone 90; eBioscience), CD40-APC (clone
1C10; eBioscience), CD44-APC (clone IM7; eBioscience),
CD45-APC (clone 30-F11; eBioscience), CD90.2-APC
(clone HIS51; eBioscience), CD105-PE (clone MJ7/18;
eBioscience), CD106-PE (clone 429; eBioscience), c-
Kit/CD117-APC (clone 3C1; Miltenyi), CD133-APC
(clone 13A4; eBioscience), CD140b-APC (eBioscience),
CD146-FITC (Miltenyi), Flk-1-APC (clone Avas12a1;
eBioscience), Lineage Cell Detection Cocktail-Biotin mouse
(Miltenyi; cat. no. 130-092-613), MHC class II-APC (clone
M5; eBioscience), NG2 chondroitin sulfate proteoglycan
(Chemicon/Millipore; cat. no. AB5320), Sca-1-APC (clone
D7; eBioscience), rat IgG2a isotype control-APC (clone
eBR2a; eBioscience), rat IgG2a isotype control-FITC (clone
eBR2a; eBioscience), rat IgG2a isotype control-PE (clone
eBR2a; eBioscience), rat mouse IgG1, 𝜅𝜅 isotype control
(clone P3; eBioscience), and Arminian hamster IgG isotype
control (clone eBio299Arm; eBioscience).
2.5. Real Time RT-PCR. Freshly isolated ALDHdim, ALDHbr,
and ALDHvery-br cells from PBS-perfused hearts from 8-
week-old mice (𝑛𝑛 𝑛 𝑛) were sorted using a Beckman Coulter
MoFlo Astrios FACS system. Total mRNA from each cell
subset was extracted using the RNeasy Micro kit (Qiagen).
e diﬀerent c-DNAs were generated using the Quantitect
reverse transcription kit (Qiagen) from total mRNA obtained
with a genomic DNA digestion step according to the man-
ufacturer’s instructions. cDNA (1 : 10 dilution) was used for
quanti�cation using the RT2 SYBRGreen qPCR Kit (Qiagen)
and the Rotor-Gene 2000 system (Qiagen) according to
the manufacturer’s instructions. Real-time PCR reactions
(in triplicates) were set up in 10 𝜇𝜇L reaction volume with
5𝜇𝜇L of RT2 SYBR Green mix, 0.4 𝜇𝜇L of 10 𝜇𝜇M RT2 qPCR
Primer Assay, 3 𝜇𝜇L cDNA, and 1.6 𝜇𝜇L water. e polymerase
was heat-activated for 10min at 95∘C, and the reactions
were then cycled 50 times (95∘C, 15 sec; 55∘C, 40 sec; 72∘C,
30 sec), followed by a melting step. Primers were obtained
from (Qiagen). Relative expression was calculated with the
comparative ΔCt method using GUSB as a reference gene.
2.6. Ex Vivo Cultures of 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑏𝑏𝑏𝑏 Cells. In two prelimi-
nary experiments, cells from enzymatically dissociated atria
and ventricles were reacted separately with Alde�uor, and
ALDHbr cells were sorted by FACS and placed in Corning
Costar 6-well plates (Sigma)with no extracellularmatrix pro-
tein coating. Ventricular ALDHbr cells grew poorly in culture,
possibly as a result of a very long sorting procedure due to
the scarcity of ALDHbr cells in the ventricular population.
erefore, atrial cells from 8-week-old mice were used in
subsequent experiments (𝑛𝑛 𝑛 𝑛 per experiment), allowing
for a marked abbreviation of the sorting procedure. ALDHbr
cells were cultured in MesenCult medium (MesenCult MSC
Basal Medium supplemented with serum-containing Mes-
enCult MSC Stimulatory Supplements-Mouse; STEMCELL
Technologies). ALDHdim cells were studied for comparison.
To assess the impact of the culture medium on cell pheno-
type, ALDHbr sorted cells were also cultured in RPMI/FCS
medium (RPMI 1640; Gibco, supplemented with 10% fetal
calf serum). e AlamarBlue assay (Promega, Madison, WI,
USA) was used to assess cell viability and growth. In a sepa-
rate experiment, cells were cultured in the presence of ima-
tinib (methanesulfonate salt, 0.1–10 𝜇𝜇M; LC Laboratories,
Woburn, MA, USA), a inhibitor of receptor tyrosine kinases
encoded by c-kit and platelet-derived growth factor receptor
B (PDGFRB). Cells were incubated with imatinib for 42 h (in
triplicates) before AlamarBlue was added. Absorbance was
measured at 570 nm and 595 nm every hour during 6 hours,
and AlamarBlue reduction was calculated.
2.7. Diﬀerentiation Potential of Expanded 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑏𝑏𝑏𝑏 Cells.
Cells sorted on the basis of high ALDH activity were cultured
for 8 months in MesenCult, which was then replaced by NH
ChondroDiﬀ Medium (for 21 days), NH OsteoDiﬀ Medium
(7 days), or AdipoDiﬀ Medium (14 days; all from Miltenyi).
Chondrogenic diﬀerentiation was assessed by immunostain-
ing for type II collagen. To assess osteogenic and adipogenic
diﬀerentiation, cells were incubated with 1% PFA for 10min,
followed by 2% Alizarin Red solution for 5min and Oil Red-
O solution for 15min, respectively, and by 3 PBS-washes.
3. Results
3.1. 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑏𝑏𝑏𝑏 Cells in Neonatal and Young Adult Hearts.
Freshly isolated nonmyocytic cells from enzymatically dis-
sociated, neonatal or 8-week-old hearts were analyzed by
�ow cytometry using the Alde�uor reagent. ALDHbr cells
amounted to 1.00 ± 0.59% of all nonmyocytic cells in the
neonatal heart (𝑛𝑛 𝑛 𝑛) and to 0.99 ± 0.55% of these cells in the
young adult heart (𝑛𝑛 𝑛 𝑛, NS; Figure 1). Within the ALDHbr
population, the percentage of ALDHvery-br cells in neonatal
hearts was higher than in young adults (52.𝑛1 ± 6.8𝑛% versus
19.𝑛9 ± 2.𝑛2%; 𝑃𝑃 𝑃 0.05).
3.2. 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑏𝑏𝑏𝑏 Cells in Atria and Ventricles. In young adult
mice, ALDHbr cells in the atrial population were more
frequent than in the ventricular (10.29 ± 8.44% versus 1.05 ±
0.78%; 𝑛𝑛 𝑛 𝑛; 𝑃𝑃 𝑃 0.05; Figure 2). Atrial ALDHbr
cells predominantly exhibited SSClo properties but a subset
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(c)
F 1: Identi�cation of ALDHbr cells in populations isolated from whole hearts from neonatal and young adult mice. Flow cytometric
analysis of ALDH activity (a). Neonatal mice. Le panel: cells were selected according to forward scatter (FSC) and side scatter (SSC)
properties using the gated region. Middle panel: cells incubated with Alde�uor substrate and the speci�c inhibitor of ALDH, DEAB were
used to establish baseline �uorescence of these cells and to de�ne the ALDHbr (R2) and the ALDHvery-br (R3) region as less than 0.1% and 0%
of total events, respectively. Right panel: cell incubationwith Alde�uor substrate in the absence of inhibitor induced a shi in FL1 �uorescence
de�ning the ALDHdim (R1), the ALDHbr (R2), and the ALDHvery-br (R3) populations (b). Eight-week-old mice (c). Bar histogram showing
ALDHbr and ALDHvery-br cell percentages (mean, SD) in neonatal and young adult mice. 𝑃𝑃 value refers to the diﬀerence between neonatal
and 8 week-old mice.
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showed intermediate-to-high SSC properties. Ventricular
ALDHbr cells exhibitedmore homogeneous SSClo properties.
3.3. Immunophenotype of Freshly Isolated𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑏𝑏𝑏𝑏 Cells. We
used a panel of mAbs to determine the cell-surface marker
pro�le of ALDHbr, ALDHvery-br, and ALDHdim cells in the
freshly isolated, nonmyocytic cardiac-derived population in
8 weeks old as well as in 24 months old mice (Figure
3). Aging hearts contained 1.36% ALDHbr cells, of which
36.8% were ALDHvery-br (pooled sample from 5 hearts).
A majority of ALDHbr and ALDHvery-br cells from young
adult hearts stained positive for Sca-1 (≈60% and ≈70%,
resp.). Substantial subsets (≈25–50%) of ALDHbr cells stained
positive for CD34, CD106, CD44, CD90, and CD105 (Figure
4). e ALDHbr population was signi�cantly enriched for
cells expressing Sca-1, CD90, CD34, CD106, andCD44 (fold-
changes: 4.2, 4.6, 6.2, 24.1, and 34.3, resp.,) whereas it was
signi�cantly depleted for cells expressing CD45 (leukocyte
common antigen), CD31 (an endothelial marker), and CD38
(fold-changes: 0.5, 0.36, and 0.22 fold). e immunopheno-
type of ALDHbr cells derived from aging hearts was similar
to that of ALDHbr cells from young adult hearts.
3.4. mRNA Expression of Selected ALDH Isoforms. mRNA
expression of ALDH1A1, ALDH1A2, ALDH1A3, and
ALDH2 isoforms was measured by real-time RT-PCR in
puri�ed ALDHdim, ALDHbr, and ALDHvery-br cells (Figure
5). Gene transcripts of all of the four ALDH isoforms could
be detected in ALDHbr and ALDHvery-br cells, whereas only
ALDH1A1 and ALDH1A2 were detectable in ALDHdim
cells. In ALDHbr and ALDHvery-br cells, ALDH1A1 was
expressed at higher levels than ALDH1A3 (2−ΔCt = 4.0 and
4.7, resp.,) and ALDH2 (2−ΔCt = 4.8 and 8.8, resp.,) while
ALDH1A2 was expressed at higher levels than ALDH1A3
(2−ΔCt = 1.7 and 12.3, resp.,) and ALDH2 (2−ΔCt = 2.1
and 23.2, resp.). In addition, ALDH1A1 was expressed at
higher levels in ALDHbr and ALDHvery-br cells compared
to ALDHdim cells (2−ΔΔCt = 2.0 and 3.5, resp.). ALDH1A2
expression was higher in ALDHvery-br cells compared to
ALDHdim cells (2−ΔΔCt = 4.9) and was lowest in ALDHbr cells
(2−ΔΔCt = 0.5 versus ALDHdim). mRNA expression of three
genes implicated in angiogenesis was also measured. 2−ΔCt
values for ALDHdim, ALDHbr, and ALDHvery-br cells were as
follows: endoglin (CD105): 11.70, 10.41, and 14.86; ephrin
B4: 2.98, 0.90, and 2.60; angiopoietin 1: undetectable, 0.01,
and 0.008, respectively.
3.5. Ex Vivo Culture-Expansion of 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑏𝑏𝑏𝑏 Cells. ALDHbr
cells were puri�ed from the atrial population, which was
enriched for these cells compared to ventricles, in order
to abbreviate the FACS procedure, thereby limiting cell
damage. Puri�ed atrial ALDHbr cells grew in culture, whereas
ALDHdim cells did not, even when plated at a 10-fold higher
density compared to their ALDHbr counterparts (Figure
6(a)). However, >95%ALDHdim cells appeared to be viable,
as assessed by DAPI, immediately aer the FACS procedure.
Atrially derived bulk populations of nonmyocytic cells grew
poorly. Puri�ed ALDHbr cells gave rise to small numbers of
cell colonies, each one apparently originating from a single
cell, which formed a monolayer of plastic-adherent cells,
which could be expanded for more than 40 passages (later
passages were not tested). In one cell culture, the percentage
of ALDHbr cells at passage 7 was 11%; however, this parame-
ter was not systematically measured at various time points.
Growth rates in MesenCult medium were higher than in
RPMI/FCS medium (Figure 6(b)). is was con�rmed using
the AlamarBlue assay (Figure 6(c)). Imatinib inhibited cell
growth in a dose-dependent manner (Figure 6(d)).
3.6. Immunophenotype of Culture-Expanded 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑏𝑏𝑏𝑏 Cells.
e marker pro�le of expanded ALDHbr cells (P11-13) was
analyzed by �ow cytometry (Figure 7). Cells expanded in
MesenCult medium stained positive for Sca-1, CD29, CD44,
CD105, CD106, and, in part, CD146 and CD14.ey stained
negative for CD45, CD11b, CD31, and CD133. To assess
whether the culture medium aﬀected marker expression,
cells were also grown in RPMI/FCS. e immunophenotype
of these cells was similar to those grown in MesenCult,
although larger cell subsets stained positive for c-kit, CD140b
(PDGFRB) and NG2 chondroitin sulfate proteoglycan (Fig-
ures 7(b) and 7(c)). NG2 essentially colocalized with CD140b
and CD146 (Figure 7(d)). c-kit expression was demonstrated
by immunocytochemistry (Figure 7(e)).
3.7. Expanded Cells Express Sarcomeric 𝛼𝛼-Actinin and Dif-
ferentiate along Mesenchymal Lineages. Culture-expanded
ALDHbr cells could be induced to diﬀerentiate along adi-
pogenic, osteogenic, and chondrogenic lineages in appropri-
ate culture media, as evidence by staining with Oil red-O,
Alizarin red, Alcian blue (not shown), and type II collagen
immunostaining, respectively (Figures 8(a), 8(c) and 8(g)).
Cells cultured in MesenCult stained positive for sarcomeric
𝛼𝛼-actinin (Figure 8(e)) but negative for 𝛼𝛼-SMA and von
Willebrand factor (not shown).
4. Discussion
Growing evidence suggests high ALDH activity may be a
common feature shared by stem and progenitor cells across
normal tissues, as well as in cancer. Human UCB and BM
cells possessing high ALDH activity have shown angiogenic
activity in preclinical studies [30–32] and have been used
safely in phase I clinical trials in patients with ischemic
cardiovascular disease [33–35].
We characterized, for the �rst time, ALDHbr cells isolated
from the heart. Approximately one percent of all nonmy-
ocytic cells present in the young adult mouse heart were
ALDHbr, as measured by Alde�uor stain (Figure 1). e
neonatal heart contained a similar number of ALDHbr cells,
although with a higher proportion of cells exhibiting very
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F 2: Identi�cation of ALDHbr cells in the atrial and ventricular population from 8 week-old mice. Flow cytometric analysis of ALDH
activity (a). Le panels: atrial and ventricular cells were selected according to forward scatter (FSC) and side scatter (SSC) properties using
the gated region. Middle panels: cells incubated with Alde�uor substrate and the speci�c inhibitor of ALDH, D�AB, were used to establish
baseline �uorescence of these cells and to de�ne the ALDHbr region (R2) as less than 0.1% of total events. Right panels: cell incubation with
Alde�uor in the absence of inhibitor induced a shi in FL1 �uorescence de�ning the ALDHdim (R1) and the ALDHbr (R2) population. In
the example shown, not all of the atrial cells exhibiting a shi in FL1 �uorescence in the absence of inhibitor were found in the gated region
R2, suggesting that atrial ALDHbr cells may have been underestimated (b). Bar histogram showing percent ALDHbr cells (mean, SD) in the
ventricular and atrial population.
high ALDH activity (ALDHvery-br) compared to the young
adult heart. e frequency of ALDHbr cells in the population
isolated from the atria was approximately 10-fold higher than
in cells derived from ventricles (Figure 2). is observation
has analogies with previous reports on increased numbers of
putative stem/progenitor cells, such as DNA-label retaining
cells in rodents [36, 37] and c-kit+ cells in human [38], in
atria relative to ventricles. In the present study, ALDHbr
cells isolated from atria and ventricles exhibited slightly
diﬀerent side scatter (SSC) properties. Most atrial ALDHbr
BioMed Research International 7
1000
800
600
400
200
0
10008006004002000
S
S
C
FSC ALDH
DEAB
R1 R2
0.1%
R3
0%
No DEAB
R1 R2
R3
0.83%
0.31%
100 101 102 103 104 100 101 102 103 104 10
0 101 102 103 104 100 101 102 103 104 10
0 101 102 103 104 10
0 101 102 103 104 100 101 102 103 104 10
0 101 102 103 104 100 101 102 103 104
100 101 102 103 104 100 101 102 103 104 10
0 101 102 103 104 10
0 101 102 103 104 100 101 102 103 104 100 101 102 103 104 10
0 101 102 103 104 10
0 101 102 103 104
100 101 102 103 104 100 101 102 103 104 100 101 102 103 104 10
0 101 102 103 104 100 101 102 103 104 10
0 101 102 103 104 100 101 102 103 104 100 101 102 103 104
100 101 102 103 104 100 101 102 103 104 100 101 102 103 104 100 101 102 103 104
100 101 102 103 104 10
0 101 102 103 104 100 101 102 103 104 100 101 102 103 104
100 101 102 103 104 100 101 102 103 104 100 101 102 103 104 100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
0
2
4
6
8
10
0
2
4
6
8
10
0
2
4
6
8
10
0
2
4
6
8
10
0
2
4
6
8
10
0
2
4
6
8
10
0
2
4
6
8
10
0
2
4
6
8
10
0
2
4
6
8
0
2
4
6
8
0
2
4
6
8
0
2
4
6
8
0
2
4
6
8
0
2
4
6
8
0
2
4
6
8
0
2
4
6
8
200
400
600
800
1000
0
200
400
600
800
1000
0
200
400
600
800
1000
0
200
400
600
800
1000
0
200
400
600
800
1000
0
200
400
600
800
1000
0
200
400
600
800
1000
0
200
400
600
800
1000
0
200
400
600
800
1000
0
200
400
600
800
1000
0
200
400
600
800
1000
0
200
400
600
800
1000
0
200
400
600
800
1000
0
200
400
600
800
1000
0
0
2
4
6
8
0
2
4
6
8
0
2
4
6
8
0
2
4
6
8
0
2
4
6
8
0
2
4
6
8
0
2
4
6
8
0
2
4
6
8
0
2
4
6
8
0
2
4
6
8
CD31
CD49a
CD105 CD106
CD90
CD40
200
400
600
800
1000
0
100 101 102 103 104
CTRL Sca-1 CD44
M1 M1 M1
M1M1
M1 M1
M1
M1
M1
M1
M1
M1
M1M1
M1
M1
M1
M1
M1
M1
M1
M1
M1
M1
M1
M1 M1 M1 M1
M1 M1 M1 M1
M1
M1
M1
M1 M1 M1 M1
CTRL CD34
CTRL Lin CD38
0.2% 15.5%
44.5% 0.5%
0% 0.3% 10.5% 3% 6.8% 2%
58.5% 29.7% 29% 0% 2.1% 1.9% 2.9% 27.3%
76.2% 8.4% 11.6% 0% 0.5% 1.1% 0.4% 13.6%
13.5%1.6%7.4%11.2%0.2%
13.1% 32.8% 4.5%
13.6%0.4%0.5%
1.1%
1.1%
8 week-old
1000
800
600
400
200
0
S
S
C
100 101 102 103 104
1000
800
600
400
200
0
S
S
C
ALDH
100 101 102 103 104
CD45
A
L
D
H
d
im
A
L
D
H
b
r
A
L
D
H
ve
ry
-b
r
(a)
1000
800
600
400
200
0
10008006004002000
S
S
C
FSC
DEAB
R1 R2
0.1%
R3
0%
No DEAB
R1 R2
R3
1.6%
0.3%
200
400
600
800
1000
0
100 101 102 103 104
200
400
600
800
1000
0
100 101 102 103 104
100 101 102 103 104
200
400
600
800
1000
0
100 101 102 103 104
200
400
600
800
1000
0
100 101 102 103 104
200
400
600
800
1000
0
100 101 102 103 104
200
400
600
800
1000
0
100 101 102 103 104
200
400
600
800
1000
0
100 101 102 103 104
200
400
600
800
1000
0
100 101 102 103 104
200
400
600
800
1000
0
100 101 102 103 104
200
400
600
800
1000
0
200
400
600
800
1000
0
200
400
600
800
1000
0
200
400
600
800
1000
200
400
600
800
1000
00
200
400
600
800
1000
0
100 101 102 103 104
100 101 102 103 104 100 101 102 103 104 100 101 102 103 104 100 101 102 103 104 100 101 102 103 104
0
5
10
15
20
100 101 102 103 104
0
5
10
15
20
100 101 102 103 104
0
5
10
15
20
100 101 102 103 104
100 101 102 103 104 100 101 102 103 104 100 101 102 103 104 100 101 102 103 104 100 101 102 103 104 100 101 102 103 104 100 101 102 103 104 100 101 102 103 104
100 101 102 103 104 100 101 102 103 104 100 101 102 103 104 100 101 102 103 104
100 101 102 103 104 100 101 102 103 104 100 101 102 103 104 100 101 102 103 104
100 101 102 103 104 100 101 102 103 104 100 101 102 103 104 100 101 102 103 104
0
5
10
15
20
0
5
10
15
20
0
5
10
15
20
0
5
10
15
20
0
5
10
15
20
0
5
10
15
20
0
5
10
15
20
0
5
10
15
20
0
5
10
15
20
0
5
10
15
20
0
5
10
15
20
0
5
10
15
20
0
5
10
15
20
0
5
10
15
20
0
5
10
15
20
0
5
10
15
20
0
5
10
15
20
0
5
10
15
20
0
5
10
15
20
0
5
10
15
20
0
5
10
15
20
CTRL Sca-1 CD44
0.2%
CD31 CD105 CD106CTRL CD34
CTRL Lin CD38
Flk1
c-Kit CD133
26.6% 25.9% 3.9% 1.5% 32.6% 2.5% 17.4% 4.1%
64.3% 26.2% 34.9% 0.5% 7.3% 2% 10.2% 35.5%
83.6% 5.1% 12.7% 0.2% 6.1% 1.2% 7.6% 4.8%
39.2%1.8%1.8% 1.4%
8.9%3%0.4% 0.4%
0%0% 1.7% 7.3%
M1 M1 M1 M1 M1
M1 M1 M1 M1
M1 M1 M1 M1
M1M1 M1 M1 M1
M1 M1 M1 M1
M1 M1 M1 M1
M1 M1 M1 M1
M1 M1 M1 M1
M1 M1 M1 M1
1000
800
600
400
200
0
S
S
C
ALDH
100 101 102 103 104
ALDH
100 101 102 103 104
24 month-old
1000
800
600
400
200
0
S
S
C
0.2%
CD45
M1
A
L
D
H
d
im
A
L
D
H
b
r
A
L
D
H
ve
ry
-b
r
(b)
F 3: Freshly isolated ALDHbr cells from young adult hearts (upper panel; (a)) and from aging hearts (lower panel; (b)) were analyzed
by �ow cytometry for ALDH expression in combination with the expression of cell-surface markers. Cells were incubated with Alde�uor
substrate and an inhibitor of ALDH (D�AB), or with Alde�uor alone, to establish R�, R�, and R3 gates for ALDHdim (blue), ALDHbr, and
ALDHvery-br cells (both green), respectively. ese populations were subsequently analyzed for expression of markers. Cytograms for each
surfacemarker in each cell population are shown (the surfacemarkers indicated for the cytograms ofALDHdim cells also refer to the cytograms
of the respective ALDHbr and ALDHvery-br populations; corresponding cytograms are aligned vertically. Percentages of positive cells are
indicated (CTRL; isotype-matched irrelevant IgG).
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F 4: Flow cytometric analysis of the expression of cell-surface antigen markers in freshly isolated nonmyocytic cardiac cells from
8-week-old mice. Data are percentages (mean, SD) of positive cells for the indicated markers, subdivided into three groups: those
signi�cantly enriched, those signi�cantly depleted, and those neither enriched nor depleted in the ALDHbr population. Yellow bars
indicate bulk populations of cardiac-derived cells, green bars indicate ALDHbr cells, and blue bars indicate ALDHvery-br cells. Numbers are
enrichment/depletion factors for the indicated surface markers in the ALDHbr population (∗∗∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃, ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃 versus ALDHdim cells).
cells showed SSClo properties but a small subset possessed
intermediate SSC properties. In contrast, ventricular ALDHbr
cells uniformly exhibited SSClo properties.e original char-
acterizations of ALDHbr cells from humanUCB revealed that
the ALDHbrSSClo population was enriched 50- to 100-fold
for primitive hematopoietic progenitors [11, 15]. In several
studies, SSClo properties therefore were associated with
the traditional de�nition of ALDHbr hematopoietic cells.
However, other studies focused on ALDHbrLin− (lineage-
depleted) cells [13, 14, 16]. �e de�ned ALDHbr cells based
solely on ALDH activity, regardless of SSC and lineage prop-
erties. is methodological approach aﬀected ALDHbr cell
counts onlymarginally, given the predominantALDHbrSSClo
phenotype. Nevertheless, the slightly diﬀerent SSC properties
of atrial and ventricular cells may suggest diﬀerences in the
cellular composition of the ALDHbr population depending
on the cardiac chamber of origin. is issue remains to be
addressed in future studies.
Freshly isolated ALDHbr cells exhibited a heterogeneous
phenotype, re�ecting amixture of diﬀerent cell types (Figures
3 and 4). is population was signi�cantly enriched for cells
expressing Sca-1, the early hematopoietic and EPC marker
CD34, the MSC marker CD90, the hyaluronic acid receptor
CD44, and vascular cell adhesionmolecule-1 (CD106). CD44
and CD106 were the most highly enriched markers in
the ALDHbr versus ALDHdim population (34.3 and 24.1
fold-increases, resp.). Previous studies associated CD44 and
CD106 expression with MSCs [39]. However, a recent study
showed that freshly isolated murine and human BM stromal
cells did not express CD44 andCD106, but they could acquire
expression of these antigens in vitro [40]. CD44+CD24−
cells have been proposed to represent cancer stem cells in
breast cancer [41], as well as in head and neck squamous
cell carcinoma (the latter includes an ALDH1+CD44+CD24−
stem cell subset) [42]. In the present study, ALDHvery-br
cells were highly enriched for Sca-1 and CD90, but only
moderately so for CD34, possibly re�ecting a predominant
MSC-like subpopulation with fewer hematopoietic/vascular
progenitors compared to ALDHbr cells with lower levels
of ALDH activity. e ALDHbr population was signi�-
cantly depleted for common leukocyte antigen (CD45), the
endothelial marker CD31, and CD38 (an antigen expressed
by the diﬀerentiating progeny of CD34+CD38– hematopoi-
etic/vascular progenitors). ALDHvery-br cells were further
depleted for lineage diﬀerentiation markers compared to
ALDHbr cells. us, the ALDHbr population was enriched
for MSC-like progenitors and depleted for diﬀerentiating
hematopoietic and endothelial cells.
Puri�ed ALDHbr atrial cells could be expanded ex vivo,
whereas their ALDHdim counterparts could not. Because
the atrial population contained more ALDHbr cells than
the ventricular population, atrial cells were used for the
puri�cation of ALDHbr cells in order to shorten the sorting
procedure, and therefore to attenuate cell damage. Puri�ed
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F 5: Real time RT-PCR analysis of gene transcripts of selected ALDH isoforms (a). FAC sorting of freshly isolated ALDHdim (R1),
ALDHbr (R2), and ALDHvery-br (R3) atrial cells from 8-week-old mice (b). RT-PCR analysis of ALDH1A1, ALDH1A2, ALDH1A3, and
ALDH2 gene transcripts (data are 2−ΔCt values using GUSB as a reference gene). ND: not detectable.
ALDHbr cells formed a few plastic-adherent colonies in
each culture well. Each colony apparently originated from
a single cell, providing observational evidence of clonal
expansion, even though this was not �rmly established
using a clonogenic assay. e mechanism responsible for
the selective growth of ALDHbr cells in culture remains
unclear. To initially address this question, we determined
the respective contributions of selected ALDH isozymes
to ALDH activity, measured by Alde�uor stain. Fi�een
ALDH isozymes have been described in mice [43] and 19
in human [9, 44]. ey play diﬀerent biological roles that
vary among cell types and species. ALDH1A1, the ALDH
isozyme most highly overexpressed in human BM ALDHbr
versus ALDHdim cells [44], was believed to be responsible for
ALDHactivity, measured byAlde�uor stain, in BM and other
tissues.However, recent �ndings in geneticallymodi�edmice
demonstrated that ALDH1A1 was dispensable for stem cell
function in the mouse hematopoietic and nervous systems
[45]. ALDH1 was identi�ed as a marker of normal and
malignant human mammary stem cells and a predictor of
poor clinical outcome in breast cancer [28]. In a distinct
study, shRNA knock-down data indicated that ALDH1A3,
not ALDH1A1, correlated best with ALDH activity in breast
cancer stem cells [46]. ALDH1A1 andALDH3A1were highly
expressed in nonsmall cell lung cancer, and knock-down of
these ALDH isoformswere associatedwith in vitro functional
changes in the proliferation and motility of these cells [47].
Human ALDH1A1, ALDH1A2, ALDH1A3, and ALDH8A1
function in retinoic acid cell signaling via retinoic acid
production by oxidation of all-trans-retinal and 9-cis-retinal
[6, 46]. ALDH2, a mitochondrial isozyme that mediates both
the detoxi�cation of reactive aldehydes and the bioactivation
of nitroglycerin to nitric oxide, mediates cytoprotection in
the heart [48]. Recent data indicated that the aldehyde-
oxidizing activity of mouse HSCs, measured by Alde�uor
stain, was due to the ALDH2 isozyme and correlated with
protection against acetaldehyde toxicity [49]. Mice de�cient
in both Fanconi anemia pathway-mediated DNA repair and
acetaldehyde detoxi�cation showed more than a 6��-fold
reduction in the HSC pool.
Based on these reports, we measured the expression
of ALDH1A1, ALDH1A2, ALDH1A3, and ALDH2 gene
transcripts in puri�ed ALDHdim, ALDHbr, and ALDHvery-br
cardiac-derived cells (Figure 5). Expression of ALDH1A1
was lowest in ALDHdim cells, intermediate in ALDHbr
cells, and highest in ALDHvery-br cells (2−ΔΔCt = 3.5 using
10 BioMed Research International
ALDHbr (d7) ALDHbr (d12) ALDHdim (d7)
(a)
P
as
sa
ge
0
5
10
15
20
25
30
35
0 50 100 150 200
RPMI/FCS
MesenCult
Days
P0
P7
P11
P29
(b)
Hours
0
5
10
15
20
25
1 2 3 4 5 6
RPMI/FCS
MesenCult
A
R
 (
%
)
(c)
0
20
40
60
80
100
0 0.1 1 10
R
el
at
iv
e 
gr
o
w
th
 (
%
)
*NBUJOJC 	঴.

(d)
F 6: Ex vivo culture-expansion of ALDHbr atrial cells (a). Photomicrographs of ALDHbr cells cultured for 7 and 12 days in MesenCult
medium. ALDHdim cells were dead by day 7 (b). Growth curves of cells in diﬀerent growth media. Cells were cultured in MesenCult medium
up to P10 (arrow). From P11 on, MesenCult was either maintained or replaced by RPMI/FCS. Symbols (squares and diamonds) indicate cell
passage (no data available from P1 to P7; dotted line) (c). AlamarBlue assay on cells (P40) cultured in either MesenCult or RPMI/FCS (AR%:
percent AlamarBlue reduction) (d). Dose-response study of Imatinib with respect to growth inhibition of expanded ALDHbr cells (P25).
ALDHdim as a reference population). By contrast, expression
of ALDH1A2 was lowest in ALDHbr cells, intermediate in
ALDHdim cells, and highest in ALDHvery-br cells (2−ΔΔCt =
4.9 versus ALDHdim). Expression of ALDH1A3 and ALDH2
was detectable in ALDHbr and ALDHvery-br cells, albeit at
lower levels compared to ALDH1A1 and ALDH1A2, but
not in ALDHdim cells. us, ALDH1A1 correlated best with
ALDH activity; however, contributory roles of ALDH1A2,
ALDH1A3, and ALDH2 to ALDH activity are possible based
on our data. While the present analysis included the four
ALDH isoformsmost oen associated with ALDH activity in
previous reports [44–49], it should be completed to include
the remaining ALDH isoforms. In addition, shRNA knock-
down experiments are needed for identifying the ALDH
isozyme(s) responsible for ALDH activity in these cells.
Recent data suggested BM and UCB ALDHbr cells
might repair ischemic tissues in vivo by releasing angio-
genic factors [30–32]. A comparison of gene expression
pro�les by ALDHbr and ALDHdim human BM cells identi�ed
three angiogenic factors (endoglin/CD105, ephrin B4, and
angiopoietin-1) as the most highly overexpressed factors in
ALDHbr versus ALDHdim cells (fold-changes: 66.9, 64.6, and
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c-Kit
Hoechst 33342
Hoechst 33342 Merge
MergeCTRL
(e)
F 7: (a)/(b) Flow cytometric analysis of ALDHbr atrial cells expanded in MesenCult (P11) or RPMI/FCS medium (P13). (c)
Percentages of cells (mean, SD) expressing the indicated markers (data from 3 separate experiments in MesenCult). (d) Two-color analysis
of pericyte/perivascular markers (NG2, CD146, and CD140b; numbers are cell percentages). (e) c-kit immunostaining of expanded ALDHbr
cells. Nuclear staining with Hoechst 33342 (CTRL, secondary Ab only as a control).
10x
(a)
40x
(b)
20x
(c)
20x
(d)
20x
(e)
20x
(f)
10x
(g)
F 8: Diﬀerentiation potential of expanded ALDHbr cells. (a) Photomicrograph showing intracellular fat droplets in cells cultured in
adipogenic medium. (b) Positive Oil Red-O staining of intracellular droplets. (c) Positive type-II collagen immunostaining (green) in cells
cultured in chondrogenic medium. (d) Type-II collagen immunostaining of leg cartilage, as a positive control. (e) Positive sarcomeric 𝛼𝛼-
actinin immunostaining (green) of an ALDHbr cell (the protein does not show clear sarcomeric distribution). (f) Corresponding negative
control (secondary Ab only). (g) Positive Alizarin Red staining of expanded ALDHbr cells cultured in osteogenic medium.
7.0, resp.) [44]. We therefore measured mRNA expression
of these angiogenic genes in cardiac-derived cells but found
no correlation with ALDH activity (besides the preliminary
observation that angiopoietin-1 transcripts were detectable
in ALDHbr and ALDHvery-br cells but not in ALDHdim cells).
e angiogenic potential of cardiac-derived ALDHbr cells
remains to be addressed in future studies. Previous reports
showed that ALDHbr MSCs from human UCB were more
responsive to hypoxia than theirALDHdim counterparts, with
upregulation of Flt-1, CXCR4, and angiopoietin-2 [50]. e
same group reported that ALDHdim EPCs, but not ALDHbr
EPCs, from human UCB upregulated hypoxia-inducible fac-
tor proteins as well as VEGF, CXCR4, and GLUT-1 mRNAs
under hypoxic conditions [22].e introduction ofALDHdim
EPCs signi�cantly reduced ischemic tissue damage in a
mouse �ap model, whereas ALDHbr EPCs were ineﬀective.
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ese �ndings suggested varying angiogenic activities of
ALDHbr cells depending on the cell type studied.
In the present study, plastic-adherent cell clusters grew
rapidly and could be passaged more than 40 times (later
passages were not tested). Growth rates in complete Mes-
enCult medium were higher than in RPMI/FCS (Figure
6). Imatinib, which selectively inhibits PDGFRB (CD140b)
and c-kit tyrosine kinases with a similar potency [51],
reduced cell proliferation in a dose-dependent manner.
Expression of PDGFRB and c-kit was detected in subsets
of expanded cells. e eﬀect of Imatinib might re�ect a
role for PDGFRB and/or c-kit in the proliferation of these
cells. Previous studies showed that ALDHbr MSCs fromUCB
proliferated more than their ALDHdim counterparts [50],
whereas ALDHdim EPCs proliferated more than ALDHbr
EPCs [22]. Proliferative properties correlatedwith angiogenic
activities in these populations. Again, the association of
ALDH and proliferation may vary among cell types. e
immunophenotype of expandedALDHbr cardiac cells resem-
bled that of freshly isolated ALDHbr cells (Figure 7). Positive
stains for pericytic markers (NG2, CD146, and CD140b)
were consistent with a MSC-like phenotype. It has been
shown that perivascular cells of arterioles and capillaries
frommany tissues express pericytic markers and showMSC-
like and angiogenic features [52–54]. In the present study,
expanded cells stained positive for sarcomeric 𝛼𝛼-actinin,
a cardiac marker, and exhibited diﬀerentiation potential
along multiple mesenchymal lineages. Previous data showed
that aldehyde dehydrogenase activity did not increase the
chondrogenic potential of human adipose-derived adult
stem cells [55]. Recent reports showed that human BM
contained ALDHbr multipotential mesenchymal progenitor
cells (MPCs), besides ALDHbr HSCs and EPCs [12, 56].
eseMPCs strongly expressedALDH, expressed embryonic
markers not present in mesenchymal cells, and could be
diﬀerentiated to microvascular endothelial cells and mes-
enchymal cells. e latter lacked strong ALDH expression
and could not be induced to back diﬀerentiate into MPCs.
We observed a loss of ALDHbr cells with cell passage
(e.g., only 11% of cells at passage 7 were still ALDHbr).
Whether this loss of ALDHbr cells with time re�ected cellular
adaptation to ex vivo conditions or the replacement of early
progenitors by a progeny of late progenitor and precursor
cells remains unclear. e observation that growth rates and
the immunophenotype remained stable for more than 30 and
10 passages, respectively, seemed not to support cell diﬀeren-
tiation. ALDH as a stem/progenitor cell marker has chie�y
been used in freshly isolated cells and tissues, as opposed
to expanded cell populations. e signi�cance of ALDH
in culture-expanded cells is unclear, as is its contribution
to stem cell fate. e aforementioned observation that the
mesenchymal cell progeny ofALDHbr humanBMcells lacked
strong ALDH expression and could not be induced to back
diﬀerentiate into MPCs suggested a parallel loss of ALDH
expression and cell potency [56].
In conclusion, cardiac-derived ALDHbr cells are pro-
genitor cells with MSC-like phenotype and function and
with superior ex vivo growth characteristics compared to
their ALDHdim counterparts. Further studies are needed for
assessing the regenerative potential of these cells in animal
models of heart disease.
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